Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 plus nintedanib in advanced hepatocellular carcinoma
CTR20210013Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Mar 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in hepatocellular carcinoma (HCC), sponsored by Alphamab Oncology. Started Mar 2021; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20210013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210013.